09.05.2017 Views

Encyclopedia of Health and Medicine

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

lymphoma 153<br />

There are five identified subtypes <strong>of</strong> Hodgkin’s<br />

lymphoma:<br />

• lymphocyte-predominant (also called nodular<br />

lymphocyte predominance)<br />

• nodular sclerosis<br />

• lymphocyte-rich (also called classical)<br />

• mixed cellularity<br />

• lymphocyte-depleted<br />

Treatment regimens <strong>and</strong> prognoses differ for<br />

each subtype. Nodular sclerosis Hodgkin’s lymphoma<br />

is the most common subtype, accounting<br />

for about two thirds <strong>of</strong> diagnoses, <strong>and</strong> tends to be<br />

moderately progressive. Lymphocyte-predominant<br />

Hodgkin’s lymphoma tends to progress slowly;<br />

lymphocyte-depleted Hodgkin’s lymphoma tends<br />

to be quite aggressive with rapid progression <strong>and</strong><br />

frequent metastasis to organs outside the lymphatic<br />

system. In general, the higher the number <strong>of</strong> Reed-<br />

Sternberg cells, the more aggressive the cancer.<br />

Non-Hodgkin’s Lymphoma<br />

The non-Hodgkin’s lymphomas account for about<br />

85 percent <strong>of</strong> diagnosed lymphoma <strong>and</strong> most<br />

commonly affect people over age 60, though can<br />

develop at any age. There are several dozen subtypes<br />

<strong>of</strong> non-Hodgkin’s lymphoma, currently classified<br />

according to the type <strong>of</strong> tumor (also called a<br />

neoplasm) <strong>and</strong> its characteristics. Doctors further<br />

classify non-Hodgkin’s lymphomas as to whether<br />

they are aggressive (rapidly growing)—high or<br />

intermediate grade—or indolent (slow growing)—<br />

low grade.<br />

NON-HODGKIN’S LYMPHOMA SUBTYPES<br />

AIDS-related<br />

anaplastic large cell<br />

angioimmunoblastic blastic natural killer (NK)<br />

BONE<br />

Burkitt’s<br />

CENTRAL NERVOUS SYSTEM (CNS) cutaneous T-cell<br />

diffuse large cell<br />

diffuse small noncleaved cell<br />

eyelid<br />

follicular<br />

immunoblastic<br />

lymphoblastic<br />

lymphoplasmacytic<br />

mantle cell<br />

marginal zone<br />

MUCOSA-ASSOCIATED LYMPHOID<br />

mycosis fungoides<br />

TISSUE (MALT)<br />

nodal marginal zone nasal NK/T<br />

small lymphocytic<br />

ocular (EYE)<br />

splenic marginal zone<br />

Symptoms <strong>and</strong> Diagnostic Path<br />

Many people do not have symptoms <strong>of</strong> lymphoma<br />

at the time <strong>of</strong> diagnosis. Rather, the doctor detects<br />

characteristic abnormalities in diagnostic blood<br />

tests conducted for other reasons, <strong>of</strong>ten as part <strong>of</strong><br />

a ROUTINE MEDICAL EXAMINATION. When symptoms<br />

are present they can be vague <strong>and</strong> generalized,<br />

typical <strong>of</strong> common viral infections though they<br />

tend to persist or recur rather than resolving. Such<br />

symptoms may include<br />

• painless swellings in the lymph nodes, most<br />

noticeable in the axillae (underarms), neck, or<br />

groin (LYMPHADENOPATHY)<br />

• unexplained, frequent fevers<br />

• unintended or unexplained weight loss<br />

• pr<strong>of</strong>use sweating at night<br />

• tiredness, fatigue, or lethargy<br />

• unexplained, generalized itching (PRURITUS)<br />

The diagnostic path begins with the doctor’s<br />

physical examination, which may reveal<br />

SPLENOMEGALY (enlarged spleen) or detect enlarged<br />

lymph nodes beneath the collarbone or in the<br />

abdomen. Diagnostic blood tests <strong>and</strong> bone marrow<br />

biopsy demonstrate the proliferation <strong>of</strong> lymphocytes.<br />

Other diagnostic procedures the oncologist<br />

may conduct include tissue biopsy <strong>of</strong> swellings,<br />

COMPUTED TOMOGRAPHY (CT) SCAN or MAGNETIC RESO-<br />

NANCE IMAGING (MRI) to detect the presence <strong>of</strong><br />

tumors deep within the body, POSITRON EMISSION<br />

TOMOGRAPHY (PET) SCAN to examine the lymphatic<br />

network, <strong>and</strong> specialized immunocytology tests to<br />

determine the subtype <strong>of</strong> lymphoma. Based on<br />

the diagnostic findings the oncologist assesses the<br />

status <strong>of</strong> the lymphoma, assigning it a stage classification.<br />

Oncologists further designate a grade for<br />

non-Hodgkin’s lymphoma that characterizes the<br />

level <strong>of</strong> aggressiveness. These assessments determine<br />

the appropriate treatment regimens <strong>and</strong> help<br />

valuate the prognosis (likelihood <strong>of</strong> REMISSION <strong>and</strong><br />

survival).<br />

Treatment Options <strong>and</strong> Outlook<br />

Treatment regimens depend on the subtype, stage,<br />

<strong>and</strong> for non-Hodgkin’s lymphomas the grade <strong>of</strong><br />

the cancer as well as the person’s age <strong>and</strong> overall<br />

health status. The typical treatment approaches,<br />

<strong>of</strong>ten administered in combinations, include

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!